Scarica l'app Stockscreener
1.726
0.94%
0.026
Precedente Chiudi:
$1.70
Aprire:
$1.68
Volume 24 ore:
336.78K
Relative Volume:
0.45
Capitalizzazione di mercato:
$227.68M
Reddito:
-
Utile/perdita netta:
$-101.70M
Rapporto P/E:
-0.9103
EPS:
-1.8961
Flusso di cassa netto:
$-84.35M
1 W Prestazione:
-12.45%
1M Prestazione:
-13.33%
6M Prestazione:
-7.24%
1 anno Prestazione:
+250.20%
Intervallo 1D:
$1.67
$1.91
Intervallo di 1 settimana:
$1.60
$1.97
Portata 52W:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.73 | 223.73M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
437.79 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.18 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
792.32 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.03 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
307.19 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Iniziato | Wells Fargo | Overweight |
| 2026-03-06 | Ripresa | UBS | Buy |
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer to Advance Cancer Therapy Pipeline 1 - Minichart
ALX Oncology names Jeff Knight as chief development officer By Investing.com - Investing.com South Africa
ALX Oncology Appoints Jeff Knight to Lead Development - TipRanks
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Bitget
Jeff Knight joins ALX Oncology (NASDAQ: ALXO) as development chief - Stock Titan
ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan
Profit Recap: What are the risks of holding ALX Oncology Holdings Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Can ALX Oncology Holdings Inc reach all time highs this year2026 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Geopolitics Watch: Is ALX Oncology Holdings Inc attractive at current valuation2026 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Block Trades: Will ALX Oncology Holdings Inc benefit from government policyPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Performance Based Restricted Stock Units of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Recap Report: Is ALX Oncology Holdings Inc a stock for growth or value investors2026 Retail Activity & Free Reliable Trade Execution Plans - baoquankhu1.vn
ALX Oncology Holdings (ALXO) price target increased by 38.00% to 4.69 - MSN
RSI Check: Should I invest in ALX Oncology Holdings Inc before earningsWeekly Trade Report & Verified Short-Term Plans - baoquankhu1.vn
Risk Off: Can ALX Oncology Holdings Inc reach all time highs this year2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Buy Signal: What is ALX Oncology Holdings Incs book value per shareQuarterly Trade Summary & Weekly High Momentum Picks - baoquankhu1.vn
Investment Review: Is ALX Oncology Holdings Inc benefiting from interest rate changes2026 Trends & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Insider Selling: ALX Oncology (NASDAQ:ALXO) CEO Sells 12,311 Shares of Stock - MarketBeat
ALX Oncology (ALXO) CEO sells 12,311 shares to cover tax obligations - Stock Titan
ALX Oncology (ALXO) finance SVP sells 903 shares to cover tax bill - Stock Titan
Risk Recap: Is ALX Oncology Holdings Inc attractive at current valuation2026 Update & Capital Efficient Trading Techniques - baoquankhu1.vn
Earnings Recap: Will ALX Oncology Holdings Inc stock hit new highs in YEAR2026 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of ALX Oncology Holdings (ALXO) with overweight recommendation - MSN
ALXO: Wells Fargo Initiates Coverage with Overweight Rating | AL - GuruFocus
Wells Fargo & Company Begins Coverage on ALX Oncology (NASDAQ:ALXO) - MarketBeat
Wells Fargo initiates ALX Oncology stock with overweight rating By Investing.com - Investing.com Canada
Wells Fargo Initiates ALX Oncology at Overweight With $5 Price Target - marketscreener.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
IBRX Stock Jumps on Progress in NK Cell Therapy Production - sharewise.com
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study - tradingview.com
RLMD stock surges 42% in a week: Here's what you should know - msn.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - The Globe and Mail
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail
RLMD Stock Surges 42% in a Week: Here's What You Should Know - sharewise.com
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz
ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart
ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat
ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alx Oncology Holdings Inc Azioni (ALXO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):